Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Transplantation. 2021 Nov 1;105(11):e168–e180. doi: 10.1097/TP.0000000000003776

Table 2.

Biotherapeutic targeting of human TFH cells

Type of drug Drug INN Clinical setting Trial
registration		 References
Costimulatory molecules agonists and antagonists CTLA4-Ig belatacept transplantation NCT00256750 104
Anti-CD28 lulizumab transplantation, Sjogren’s syndrome, lupus NCT04066114, NCT02265744, NCT02843659 –
Anti-CD40 bleselumab transplantation NCT01780844, NCT01279538 121, 122
Anti-CD40L dapirolizumab lupus NCT01764594 179
Anti-ICOS MEDI-570 lupus, lymphoma NCT01127321, NCT02520791 –
Anti-OX40 GBR 830 atopic dermatitis NCT02683928 141
Anti-CD70 cusatuzumab acute myeloid leukemia NCT03030612 147
Cytokines and cytokine receptors antagonist Anti-IL-6 clazakizumab transplantation, rheumatoid arthritis, COVID-19 NCT03444103, NCT01373151, NCT04363502 –
Anti-IL-6R tocilizumab transplantation, rheumatoid arthritis, giant-cell arteritis, COVID-19 NCT01594424, NCT01119859, NCT01791153, NCT04356937 180, 181, 182, 183
Anti-IL-21 BOS161721 lupus NCT03371251 –
Anti-IL-21 NNC114–0005 healthy subjects, rheumatoid arthritis NCT01208506 163
Anti-IL-21R ATR-107 healthy subjects NCT01162889 164
Anti-IL-7Rα OSE-127 healthy subjects NCT03980080 –
Anti-IL-7Rα RN168 type 1 diabetes NCT02038764 168
Anti-IL-12/IL-23 ustekinumab psoriasis, Crohn's disease, ulcerative colitis NCT00454584, NCT00771667, NCT02407236 170, 171, 172

INN, international nonproprietary name